



**SUPRIYA LIFESCIENCE LTD.**

*Creating true values that bind global health*

Date: January 24, 2025

To,  
**BSE Limited**  
Phiroze Jeejeebhoy Towers  
Dalal Street,  
Mumbai – 400 001  
**Scrip Code: 543434**

To,  
**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block G  
Bandra Kurla Complex  
Bandra (E), Mumbai – 400 051  
**Scrip Symbol: SUPRIYA**

Dear Sir (s),

**Sub: Outcome of Board Meeting in accordance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Pursuant to Regulation 33 read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that the Board of Directors of the Company at its Meeting held on Friday, January 24, 2025, inter-alia, has:

1. Considered and approved the Unaudited Financial Results for the quarter and nine month ended December 31, 2024.
2. Appointed Dr. Ganapati Dadasaheb Yadav (DIN: 02235661) as an Additional Director (Non-Executive, Independent) of the Company with effect from January 24, 2025, subject to approval of the shareholders of the Company.
3. Appointed Dr. Sunil Subhash Bhagwat (DIN: 10178976) as an Additional Director (Non-Executive, Independent) of the Company with effect from January 24, 2025, subject to approval of the shareholders of the Company.

The Financials Results will be published in newspapers as required under the Listing Regulations.

The Meeting of the Board of Directors of the Company commenced at 03:00 p.m. and concluded at 04:10 p.m.

We hereby enclose the following:

1. Copy of the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2024 along with the Limited Review Report;
2. Details under SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023.

---

**Corporate office** : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.  
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX  
CIN: L51900MH2008PLC180452 E-mail: [supriya@supriyalifescience.com](mailto:supriya@supriyalifescience.com) Website: [www.supriyalifescience.com](http://www.supriyalifescience.com)

**Factory** : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.  
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: [factory@supriyalifescience.com](mailto:factory@supriyalifescience.com)

**GOVT. RECOGNISED EXPORT HOUSE**



**SUPRIYA LIFESCIENCE LTD.**  
*Creating true values that bind global health*

---

Kindly take the above said information on your records.

Thanking you,

Yours faithfully,

**For Supriya Lifescience Limited**

**Shweta Singh**  
**Company Secretary & Compliance Officer**  
**Membership No.: A44973**

---

**Corporate office** : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.  
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX  
CIN: L51900MH2008PLC180452 E-mail: [supriya@supriyalifescience.com](mailto:supriya@supriyalifescience.com) Website: [www.supriyalifescience.com](http://www.supriyalifescience.com)

**Factory** : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.  
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: [factory@supriyalifescience.com](mailto:factory@supriyalifescience.com)

**GOVT. RECOGNISED EXPORT HOUSE**



SUPRIYA LIFESCIENCE LIMITED  
CIN No: L51900MH2008PLC180452  
207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai - 400063. CIN: L51900MH2008PLC180452  
Tel No.: +91 22 40332727; E-mail: cs@supriyalifescience.com; Website: www.supriyalifescience.com

(₹ In million)

Part I - Statement of Standalone Unaudited Financial Results for the Quarter and Nine month ended December 31, 2024

Sr.No.	Particulars	Quarter ended	Quarter ended	Quarter ended	Nine month ended	Nine month ended	Year ended
		31-12-2024	30-09-2024	31-12-2023	31-12-2024	31-12-2023	31-03-2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	<b>Income</b>						
I	Revenue from Operations	1,856.48	1,661.02	1,400.74	5,123.76	4,121.89	5,703.70
II	Other Income	20.98	25.18	30.65	68.40	84.50	106.35
III	<b>Total Income</b>	<b>1,877.45</b>	<b>1,686.20</b>	<b>1,431.39</b>	<b>5,192.16</b>	<b>4,206.39</b>	<b>5,810.05</b>
2	<b>Expenses</b>						
	a) Cost of Materials Consumed	135.97	615.81	448.43	1,309.05	1,430.74	1,914.30
	b) Purchase of Stock In Trade	-	-	-	-	-	-
	c) Change in inventories of finished goods , work in progress & stock in trade.	481.82	(156.06)	97.78	254.46	204.06	303.11
	d. Employee benefit expenses	197.72	196.85	175.64	595.42	504.94	676.38
	e. Finance Cost	5.07	4.27	4.94	12.68	15.09	21.10
	f. Depreciation & amortisation expense	49.64	47.44	39.60	143.63	118.97	158.11
	g. Other expenditure	381.44	357.25	264.00	1,032.72	807.44	1,080.15
IV	<b>Total Expenses</b>	<b>1,251.65</b>	<b>1,065.56</b>	<b>1,030.39</b>	<b>3,347.96</b>	<b>3,081.24</b>	<b>4,153.15</b>
V	Profit/(loss) before Exceptional Items & Tax (III -IV)	625.80	620.64	400.99	1,844.20	1,125.15	1,656.90
VI	Exceptional Items	-	-	-	-	-	-
VII	<b>Profit/(loss) before Tax (V-VI)</b>	<b>625.80</b>	<b>620.64</b>	<b>400.99</b>	<b>1,844.20</b>	<b>1,125.15</b>	<b>1,656.90</b>
VIII	<b>Tax Expense</b>						
	a) Current Tax	137.72	154.46	96.55	438.85	281.56	371.00
	b) Deferred Tax	20.25	4.69	6.57	29.58	21.77	94.76
IX	<b>Profit/(Loss) for the period from Continuing Operations (VII-VIII)</b>	<b>467.83</b>	<b>461.49</b>	<b>297.87</b>	<b>1,375.76</b>	<b>821.82</b>	<b>1,191.14</b>
X	Profit/(Loss) from discontinued operations before tax	-	-	-	-	-	-
XI	Tax Expense of discontinued operations	-	-	-	-	-	-
XII	Profit/(Loss) from discontinued operations after tax (X-XI)	-	-	-	-	-	-
XIII	<b>Profit/(Loss) for the period (IX+XII)</b>	<b>467.83</b>	<b>461.49</b>	<b>297.87</b>	<b>1,375.76</b>	<b>821.82</b>	<b>1,191.14</b>
XIV	<b>Other Comprehensive Income</b>						
	A (i) Items that will not be reclassified to profit or loss	0.81	(2.90)	3.61	(2.83)	21.23	21.69
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	-0.20	0.73	(0.91)	0.71	(5.34)	(5.46)
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV	<b>Total Comprehensive Income for the period (XIII+XIV)</b>	<b>468.43</b>	<b>459.33</b>	<b>300.57</b>	<b>1,373.65</b>	<b>837.71</b>	<b>1,207.37</b>
XVI	Earnings per equity Share (for continuing operation):						
	(1) Basic (In ₹)	5.82	5.71	3.70	17.07	10.21	14.80
	(2) Diluted (In ₹)	5.82	5.71	3.70	17.07	10.21	14.80
XVII	Earnings per equity Share (for discontinued operation):						
	(1) Basic (In ₹)	-	-	-	-	-	-
	(2) Diluted (In ₹)	-	-	-	-	-	-
XVIII	Earnings per equity Share (for discontinued & continuing operations):						
	(1) Basic (In ₹)	5.82	5.71	3.70	17.07	10.21	14.80
	(2) Diluted (In ₹)	5.82	5.71	3.70	17.07	10.21	14.80





---

See accompanying notes to the financial statements:

**Notes:-**

1. The unaudited Standalone financial results of the Company for the quarter and nine month ended December 31, 2024 have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013 read with the Companies (India Accounting Standards) Rules, 2015, as ammended.
2. The above unaudited standalone financial results of the Company for the quarter and nine month ended December 31, 2024 have been reviewed by the Audit Committee on January 24, 2025 and thereafter approved by the Board of Directors at their meeting held on January 24, 2025.
3. The company operates in one reportable business segment of Pharmaceutical product including ingredients and intermediaries.
4. The figures of the previous periods have been regrouped wherever necessary to conform to the current period presentation.
5. The company does not have any subsidiary/associate/joint venture company as on December 31, 2024.

Place :- Mumbai  
Date :- January 24, 2025



For and on behalf of the board of directors of  
For Supriya Lifescience Limited

A handwritten signature in black ink, appearing to read "Dr. Satish Waman Wagh".

Dr. Satish Waman Wagh  
Chairman and Whole time director  
DIN: 01456982



**KAKARIA AND ASSOCIATES LLP**  
CHARTERED ACCOUNTANTS  
UJWAL K. KAKARIA B.Com., B.L., F.C.A.  
SUBHASH S. KOTADIA B.Com. (HONS.) F.C.A.  
JAIPRAKASH H. SHETHIYA B.Com, F.C.A.  
AMAR J. BHANUSHALI B.Com, D.T.M., F.C.A.  
VINAYAK P. BAFANA B.Com., F.C.A.

YOUR REF.:  
OUR REF. :  
DATE : 24.01.2025


**Independent Auditor's Review Report on Quarterly Unaudited Financial Results of the Company Pursuant to the Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

To,  
Board of Directors of Supriya Lifescience Limited,

1. We have reviewed the accompanying statement of unaudited financial results of **Supriya Lifescience Limited** ("the Company") for the quarter ended 31<sup>st</sup> December, 2024, ("the Statement"), being submitted by the company pursuant to the requirements of Regulation 33 and 52 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended (the "Listing regulations")
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and 52 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries,

802, Lotus Trade Centre, Near D.N. Nagar Metro Station, New Link Road, Andheri - West,  
Mumbai - 400 053. Email: [mumbai.kakaria@gmail.com](mailto:mumbai.kakaria@gmail.com)  
Website: [www.kakariaassociates.com](http://www.kakariaassociates.com)

*Cell*





**KAKARIA AND ASSOCIATES LLP**

CHARTERED ACCOUNTANTS

UJWAL K. KAKARIA B.Com., B.L., F.C.A.

SUBHASH S. KOTADIA B.Com. (HONS.) F.C.A.

JAIPRAKASH H. SHETHIYA B.Com, F.C.A.

AMAR J. BHANUSHALI B.Com, D.T.M., F.C.A.

VINAYAK P. BAFANA B.Com., F.C.A.

YOUR REF.:

OUR REF.:

DATE : 24.01.2025

primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under or by the Institute of Chartered Accountants


of India and other recognized accounting practices and policies has not disclosed the information

required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated 14<sup>th</sup> October, 2021 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**FOR, KAKARIA AND ASSOCIATES LLP**


Chartered Accountants

FRN. 104558W/W100601

**Ujwal K. Kakaria**

(Partner)

M.NO. 035416

Date:- 24<sup>th</sup> January, 2025

Place: - Mumbai

UDIN: 25035416BMJKT0N7250

802, Lotus Trade Centre, Near D.N. Nagar Metro Station, New Link Road, Andheri - West,

Mumbai - 400 053. Email: [mumbai.kakaria@gmail.com](mailto:mumbai.kakaria@gmail.com)Website: [www.kakariaassociates.com](http://www.kakariaassociates.com)



**Details under SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023**

<b>Particulars</b>	<b>Dr. Ganapati Dadasaheb Yadav</b>
Reason for change viz. appointment, resignation, removal, death or otherwise	Appointment of Dr. Ganapati Dadasaheb Yadav as an Additional Director (Non-Executive Independent) of the Company, subject to approval of the Shareholders of the Company.
Date of appointment/ <del>cessation</del> (as applicable) & term of appointment	Dr. Ganapati Dadasaheb Yadav is appointed for a first term of five years commencing from January 24, 2025 to January 23, 2030, subject to approval of the Shareholders of the Company.
Brief Profile (in case of appointment).	<p>Professor Ganapati D. Yadav is one of the topmost, highly prolific, and accomplished engineering-scientists in India. He currently holds the titles of National Science Chair (SERB/DST/GOI) and Emeritus Professor of Eminence and is the former Vice Chancellor, Institute of Chemical Technology, Mumbai. He is internationally recognized by over 150 prestigious and rare awards as an academician, researcher and innovator, including his seminal contributions to education, research and innovation in Green Chemistry and Engineering, Catalysis, Chemical Engineering, Energy Engineering, Biotechnology, Nanotechnology, and Development of Clean and Green Technologies. He serves as Independent Director on the boards of Godrej Industries, Clean Science &amp; Technology, Meghmani Organics, Bhageria Industries, Astec Lifesciences and Dorf Ketal Chemicals India.</p> <p>In 2016, Professor Yadav was honoured with the Padma Shri by the President of India for his outstanding contributions to Science and Engineering. He serves as the Adjunct Professor at University of Saskatchewan, Canada, RMIT University, Melbourne, Australia, Conjoint Professor, University of New Castle, Australia, Distinguished Adjunct Professor, IIT Guwahati and Distinguished Adjunct Professor, SOA University Bhubaneswar.</p>

**Corporate office** : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.  
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX  
CIN: L51900MH2008PLC180452 E-mail: [supriya@supriyalifescience.com](mailto:supriya@supriyalifescience.com) Website: [www.supriyalifescience.com](http://www.supriyalifescience.com)

**Factory** : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.  
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: [factory@supriyalifescience.com](mailto:factory@supriyalifescience.com)



**SUPRIYA LIFESCIENCE LTD.**

Creating true values that bind global health

	<p>In 2022, Professor Yadav was elected to the US National Academy of Engineering. In 2023, he was inducted as the Fellow of the US National Academy of Inventors, becoming only the second Indian to get this prestigious and rare honour.</p> <p>He has been a member or has chaired several national and international committees of MHRD, DST, DBT, UGC, AICTE, CSIR, the PSA's on Green Chemistry, the Planning Commission's Pan India S&amp;T Committee, and the Government of Maharashtra's Rajiv Gandhi S&amp;T Commission Peers Group. He was Chairman, Research Council, CSIR-CSMCRI, member of RC of IICT Hyderabad and NIIST Trivandrum.</p> <p>He is still actively involved in guiding doctoral students, patenting, publishing, consulting, and transferring technologies to industry and has industry sponsored projects.</p>
Disclosure of relationship between Directors (in case of appointment of a director)	Dr. Ganapati Dadasaheb Yadav is not related to any Director on the Board of the Company.
Information as required pursuant to BSE Circular Ref. No. LIST/ COMP/ 14/ 2018-19 and the National Stock Exchange of India Limited with ref no. NSE/CML/2018/24, dated June 20, 2018	Dr. Ganapati Dadasaheb Yadav is not debarred from holding the office of Director pursuant to any SEBI order or any other authority.

<b>Particulars</b>	<b>Dr. Sunil Subhash Bhagwat</b>
Reason for change viz. appointment, <del>resignation, removal, death or otherwise</del>	Appointment of Dr. Sunil Subhash Bhagwat as an Additional Director (Non-Executive, Independent) of the Company, subject to approval of the Shareholders of the Company.
Date of appointment/ <del>cessation</del> (as applicable) & term of appointment	Dr. Sunil Subhash Bhagwat is appointed for a first term of five years commencing from January 24, 2025 to January 23, 2030, subject to approval of the Shareholders of the Company.
Brief Profile (in case of appointment).	Dr. Sunil Subhash Bhagwat holds a Master's degree in Chemical Engineering and a Ph.D. in Chemical Engineering. He is the Director of Indian Institute of Science Education and Research, Pune since 2023.

**Corporate office** : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.  
 Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX  
 CIN: L51900MH2008PLC180452 E-mail: [supriya@supriyalifescience.com](mailto:supriya@supriyalifescience.com) Website: [www.supriyalifescience.com](http://www.supriyalifescience.com)

**Factory** : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.  
 Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: [factory@supriyalifescience.com](mailto:factory@supriyalifescience.com)

GOVT. RECOGNISED EXPORT HOUSE



## SUPRIYA LIFESCIENCE LTD.

Creating true values that bind global health

	<p>Earlier, he was a Professor of Chemical Engineering in the Institute of Chemical Technology (earlier known as UDCT/UICT), Mumbai since 1986.</p> <p>His area of Specialization is Interfacial Science and Engineering, Artificial Neural Networks, Energy and Exergy Engineering. He is a Fellow of the Indian National Academy of Engineering and Maharashtra Academy of Sciences and was also bestowed the INSA Teacher award.</p> <p>In 2012, Dr. Bhagwat was awarded NOCIL Award of the Indian Institute of Chemical Engineers for excellence in design or Development of Process Plant or Equipment and in 2014, awarded the CSMCRI-Chemcon Distinguished Speaker Award at Chemcon.</p> <p>In 2019, he was selected for the UDCT Alumni Association's Distinguished Alumnus Award - Academic category. In 2023, he was awarded the K V Mariwala Award for Industry- Academia interactions by the Indian Chemical Council.</p> <p>Dr. Bhagwat is a past chairman of the Indian Institute of chemical Engineers (IChE) Mumbai regional Center and is the Hon Secretary of the Indian Society for Surface Science and Technology, Western India Chapter. He is an active consultant to the chemical industry and the client companies range from pharmaceutical ancillary company to an industrial research company.</p>
Disclosure of relationship between Directors (in case of appointment of a director)	Dr. Sunil Subhash Bhagwat is not related to any Director on the Board of the Company.
Information as required pursuant to BSE Circular Ref. No. LIST/ COMP/ 14/ 2018-19 and the National Stock Exchange of India Limited with ref no. NSE/CML/2018/24, dated June 20, 2018	Dr. Sunil Subhash Bhagwat is not debarred from holding the office of Director pursuant to any SEBI order or any other authority.

**Corporate office** : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.  
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX  
CIN: L51900MH2008PLC180452 E-mail: [supriya@supriyalifescience.com](mailto:supriya@supriyalifescience.com) Website: [www.supriyalifescience.com](http://www.supriyalifescience.com)

**Factory** : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.  
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: [factory@supriyalifescience.com](mailto:factory@supriyalifescience.com)

GOVT. RECOGNISED EXPORT HOUSE